MrMed Accelerates National Expansion with New Physical Infrastructure and Cold-Chain Capabilities

Chennai, India | 4 February 2025: MrMed, a direct-to-patient platform for critical care and super-specialty medicines, today announced a new phase of accelerated growth, backed by expanded physical infrastructure, enhanced cold-chain capabilities, and a growing national footprint.

(L to R) Devashish Singh, Co-founder & CEO, MrMed; Saurab Jain, Co-founder, MrMed

Underscoring its commitment to timely access to life-saving and temperature-sensitive medicines, MrMed has strengthened its on-ground presence with new operations in Guwahati, complementing its existing infrastructure in Chennai, Delhi, and Bengaluru. The expansion is designed to improve last-mile delivery and significantly reduce fulfilment timelines across regions.

Press meet Youtube Video link 👇 

As part of this phase, MrMed has also launched an offline cold-chain storage facility in Bengaluru, reinforcing the city’s position as a strategic fulfilment hub for Karnataka and the wider South India region. Chennai continues to serve as the company’s central operations and pharmacy hub.

MrMed is actively advancing plans to expand its physical infrastructure into additional cities, with a continued focus on improving access to critical and temperature-sensitive therapies nationwide.

“Access to critical care medicines should not be determined by a patient’s location,” said Devashish Singh, Co-founder & CEO, MrMed. “We are focused on building reliable, compliant systems that make super-specialty therapies accessible at scale, ensuring continuity of treatment—even beyond large metro hospitals.”

Looking ahead, MrMed is broadening its role within the healthcare ecosystem by entering allied super-specialty healthcare services, including home-based cancer care. Planned offerings include nurse-led infusions and pre- and post-chemotherapy support, aimed at reducing hospital visits and improving continuity of care during long treatment cycles.

“While speciality medicines remain central to our mission, patient needs often extend beyond drug delivery,” said Saurab Jain, Co-founder, MrMed. “By expanding into allied services such as nurse-led infusions and chemotherapy support at home, we can ease the burden on patients and caregivers while improving treatment adherence.”

Unlike platforms focused solely on oncology, MrMed supports a broad spectrum of super-specialty and critical care therapies, including treatments for cancer, HIV, hepatitis, rare diseases, and other complex conditions—many of which are not routinely stocked by neighbourhood pharmacies due to regulatory, cost, and cold-chain requirements.

MrMed partners with authorised distributors of leading global and Indian pharmaceutical companies, including Eli Lilly, Novo Nordisk, Cipla, Dr Reddy’s, and Mankind, ensuring compliant sourcing and dependable access to life-saving therapies for patients across India.

****